Eicosanoids/NNS
in/IN
breast/NN
cancer/NN
patients/NNS
before/IN
and/CC
after/IN
mastectomy/NN
./.

In/IN
19/CD
patients/NNS
with/IN
a/DT
malignant/JJ
breast/NN
tumor/NN
,/,
tumor/NN
tissue/NN
and/CC
blood/NN
were/VBD
taken/VBN
to/TO
determine/VB
the/DT
eicosanoid/NN
profile/NN
and/CC
platelet/NN
aggregation/NN
./.
=====
Values/NNS
were/VBD
compared/VBN
with/IN
those/DT
of/IN
patients/NNS
with/IN
benign/JJ
tumors/NNS
(/(
n/NN
=/JJ
4/CD
)/)
,/,
or/CC
undergoing/VBG
a/DT
mammary/JJ
reduction/NN
(/(
n/NN
=/JJ
7/CD
)/)
./.
=====
Postoperatively/RB
,/,
blood/NN
was/VBD
taken/VBN
as/RB
well/RB
in/IN
order/NN
to/TO
compare/VB
pre-/JJ
and/CC
postoperative/JJ
values/NNS
./.
=====
Eicosanoids/NNS
were/VBD
measured/VBN
in/IN
peripheral/JJ
blood/NN
monocytes/NNS
and/CC
mammary/JJ
tissue/NN
by/IN
means/NNS
of/IN
HPLC/NN
;/:
furthermore/RBR
,/,
TXA2/NN
,/,
6-keto-PGF1/NN
alpha/NN
,/,
and/CC
PGE2/NN
were/VBD
determined/VBN
by/IN
RIA/NN
./.
=====
Differences/NNS
in/IN
pre-/JJ
and/CC
postoperative/JJ
values/NNS
of/IN
cancer/NN
patients/NNS
were/VBD
seen/VBN
in/IN
plasma/NN
RIA/NN
values/NNS
:/:
PGE2/NN
and/CC
6-k-PGF1/NN
alpha/NN
were/VBD
significantly/RB
higher/JJR
preoperatively/RB
when/WRB
compared/VBN
with/IN
postoperatively/RB
,/,
however/RB
,/,
such/JJ
differences/NNS
were/VBD
seen/VBN
in/IN
the/DT
control/NN
groups/NNS
as/RB
well/RB
./.
=====
Compared/VBN
to/TO
benign/JJ
tumor/NN
or/CC
mammary/JJ
reduction/NN
test/NN
material/NN
the/DT
eicosanoid/NN
profile/NN
of/IN
tissue/NN
obtained/VBN
from/IN
malignant/JJ
mammary/JJ
tumors/NNS
showed/VBD
important/JJ
differences/NNS
./.
=====
Except/IN
for/IN
PGF2/NN
alpha/NN
,/,
HHT/NN
and/CC
15-HETE/NN
no/DT
detectable/JJ
quantities/NNS
of/IN
eicosanoids/NNS
were/VBD
found/VBN
in/IN
the/DT
non-tumor/JJ
material/NN
,/,
whereas/IN
in/IN
the/DT
malignant/JJ
tumor/NN
material/NN
substantial/JJ
quantities/NNS
of/IN
a/DT
number/NN
of/IN
eicosanoid/NN
metabolites/NNS
were/VBD
present/JJ
./.
=====
Statistically/RB
significant/JJ
correlations/NNS
could/MD
be/VB
established/VBN
between/IN
patient/histopathology/NN
data/NNS
and/CC
the/DT
results/NNS
of/IN
the/DT
platelet/NN
aggregation/NN
assays/NNS
,/,
e.g./FW
between/IN
menopausal/JJ
status/NN
and/CC
ADP/NN
aggregation/NN
;/:
oestrogen/NN
receptor/NN
(/(
+/-/CC
)/)
and/CC
collagen/NN
and/CC
arachidonic/JJ
acid/NN
aggregation/NN
,/,
inflammatory/JJ
cell/NN
infiltration/NN
score/NN
and/CC
arachidonic/JJ
acid/NN
aggregation/NN
and/CC
fibrosis/NN
score/NN
and/CC
ADP/NN
aggregation/NN
./.
=====
The/DT
results/NNS
show/VBP
that/IN
eicosanoid/NN
synthesis/NN
in/IN
material/NN
from/IN
mammary/JJ
cancer/NN
patients/NNS
is/VBZ
different/JJ
from/IN
that/DT
in/IN
benign/JJ
mammary/JJ
tissue/NN
./.
=====
The/DT
implications/NNS
,/,
in/IN
particular/JJ
,/,
in/IN
relation/NN
to/TO
future/JJ
prognosis/NN
of/IN
the/DT
patient/NN
,/,
remain/VBP
obscure/JJ
./.